BostonBioForum 2017

CABA 10th Annual Conference 美中生物医药协会2017年会暨十周年庆典

Boston Marriott Newton

10:00 AM to 6:00 PM on Saturday, May 6, 2017

2345 Commonwealth Ave, Newton, MA 02466

PLATINUM SPONSORS

药明康德 WuXi AppTec

Pfizer

先声药业 Simcere

PAT 1995 ANNIVERSARY 2015 20 YEARS

GOLD SPONSORS

江苏无锡（惠山）生命科技产业园 Jiangsu Wuxi (Huishan) Life Science & Technology Industrial Park L-PARK

PharmaAdvance

abpro

FRONTAGE moving your compound forward

SILVER SPONSORS

Eisai

Milstein Zhang & Wu LLC

TCSci TC Scientific Inc.

Morgan Stanley

凯泰资本 KAITAI CAPITAL

中国深圳市驻北美经贸代表处 North American Representative Office of Shenzhen, China

EXHIBITORS

Wyzen WB Biosciences

毓承资本 WuXi Healthcare Ventures

Medicilon

ADESIS A Universal Display Company

WuXiNextCODE Leading Genomics

Novogene

WuXi Biologics Global Solution Provider

Aberjona Laboratories, Inc.

LabNetwork

GenScript Make Research Easy

BostonBioForum 2017

CABA 10th Annual Conference 美中生物医药协会2017年会暨十周年庆典

Conference Organizing Committee

Chair

Kevin Fang, Ph.D.

Co-Chairs

Jian Shao, MBA Lan Cao, Ph.D. Bo Ying, Ph.D.

President

Eric Shi, Ph.D.

Committee

Qingqing Cao, Ph.D.
Chaoyang Dai, Ph.D.
Jeff Hang, Ph.D.
Susan Qu, Ph.D.
Zhigang Wang, Ph.D.
Bo Ying, Ph.D.
Youxin Zhang, Ph.D.

Qinglin Che, Ph.D.
Shujia Dai, Ph.D.
Jo Lee, M.Ec
Eric Shi, Ph.D.
Cindy Yang, MBA
Chunxiao Yu, Ph.D.
Xiaoyong Zhao, Ph.D.

Yin Chen, Ph.D.
Ellen Fan, MS
Shiwen Lin, Ph.D.
Xue Shui, MS
Wendy Yang, MBA
Xiangyang Yu, Ph.D.
Liping Zhou, Ph.D.

Zhihong Chen, Ph.D.
Jun Han, Ph.D.
Carrie Liu, Ph.D.
Yihan Wang, Ph.D.
Zhiyong Yang, Ph.D.
Philip Zhang, Ph.D.
Zhendong Zhu. Ph.D.

AGENDA

09:00 - 10:00 am Registration / Social Networking

10:00 - 10:05 am Opening Remarks, *Kevin Fang, Ph.D.*, Conference Chair, President-Elect, CABA

10:05 - 10:15 am Introduction of CABA, *Eric Shi, Ph.D.*, President, CABA

Session I – Novel Therapies for Cancer and Neurological Diseases

SESSION CHAIR: *Lan Cao, Ph.D.* and *Cindy Yang, MBA.*

10:15 - 10:50 am *Samarth Kulkarni, Ph.D.*, Chief Business Officer, CRISPR Therapeutics.
"CRISPR-based Therapeutics: Making it a Reality in Asian Markets"

10:50 - 11:25 am *Ken LéClair*, VP, Technical Development and Manufacturing, Editas Medicine.
"Development of Cell and Gene-Edited Products"

11:25 - 12:00 pm *Carmen Bozic, M.D.,* SVP Global Develop, Biogen.
"Innovations in Intrathecal Antisense Oligonucleotide Therapy for Neurological Diseases"

LUNCH AND VENDOR SHOW: 12:00 - 1:30 pm (Lunch Provided on Site)

LUNCHEON PRESENTATION

12:45 - 1:05 pm *John Yao, Ph.D.*, Co-founder and CEO, TC Scientific Inc.
"A CRO's View of the Pharma Landscape" hosted by *Ellen Fan, MSc*

SESSION II – Global Innovation, Investment, and Entrepreneurship

SESSION CHAIR: *Jian Shao, MBA*

1:30 - 2:05 pm *Hui Cai, Ph.D.*, VP of Corporate Alliances and Head of Communications, WuXi AppTec.
"Platform and Ecosystem for R&D Transformation"

2:05 - 2:40 pm *James Yang, Ph.D.*, President and CEO, Abpro-China.
"Strategic Partnership for Success in Biologics"

2:40 - 3:15 pm *Yongzhong Wang, Ph.D.*, President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group.

"Innovations across the Border, a Personal Journey"

3:15 - 3:50 pm *Lynn Yang, MBA*, General Manger, Sequoia Capital "Sequoia China Healthcare Investment Strategy"

3:50 - 4:20 pm COFFEE BREAK AND VENDOR SHOW

SESSION III - Global Pharma Trends, CFDA Regulatory Reform and Scientific Advancement in PD-1 Research

SESSION CHAIRS: *Wendy Yang, MBA* and *Susan Qu, Ph.D., MBA*

4:20 - 4:55 pm *Kenneth Kaitin, Ph.D.*, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

"The Global Landscape for Pharmaceutical R&D: Current Trends - Future Opportunities"

4:55 - 5:30 pm *XinYu Weng, Ph.D., MBA*, First Secretary of the Embassy of the China to the USA.

"Overview of CFDA Drug Regulatory Reform"

5:30 - 6:05 pm *Gordon Freeman*, Dana-Farber Cancer Institute, Professor, Medicine, Harvard Medical School.

"PD-1 Cancer Immunotherapy"

6:05 - 6:10 pm Closing Remarks

EVENING EVENT - 10th Anniversary Evening Celebration

**By Invitation Only*

6:10 - 6:50 pm Key Feature: Former Presidents' Documentary Film

6:50 - 7:50 pm Dinner

7:50 - 8:30 pm Performances

Speaker Bio

Dr. Samarth Kulkarni
Chief Business Officer, CRISPR Therapeutics
Samarth (Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015. At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, Sam co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications.
Sam received his Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in leading journals.

Ken LeClair, PhD
VP, Technical Development and Manufacturing
Ken LeClair received his undergraduate degree from Bowdoin College and a Ph.D. in Immunobiology from Yale University.
He did a postdoc at the MIT Center for Cancer Research and had an academic appointment as Assistant Professor of Medicine in the Immunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.
Ken left academics and worked at several small biotech companies in the Boston area before joining Novartis in 2008.
Ken spent the first 4 years at Novartis performing developability assessments for biologics candidates coming into Development from the NIBR discovery research organization.
He then performed the technical diligence for the CART immunotherapy collaboration with UPenn and helped to establish the Novartis Cell and Gene therapy Unit, until it was recently reorganized.
He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.

Carmen Bozic, M.D.
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen's therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry. Her Global Development organization includes Regulatory Affairs, Safety and Benefit-Risk Management, Biometrics, Global Clinical Operations, R&D Compliance, Medical Writing, as well as Development Sciences in Japan. Previously, she oversaw Clinical Development in the Neurology, Immunology and Hematology Therapeutic Areas as well as Preclinical Safety and was the former SVP and Global Head of Safety and Benefit-Risk Management at Biogen. In her leadership roles at Biogen, Dr. Bozic has overseen regulatory filings and approvals of multiple therapies, including TYSABRI (natalizumab), AVONEX (interferon beta-1a) pre-filled syringe and auto-injector, TECFIDERA (dimethyl fumarate), PLEGRIDY (pegylated interferon beta-1a) and ZINBRYTA (daclizumab) for the treatment of multiple sclerosis, as well as ELOCTATE (Factor VIII Fc fusion protein) and ALPROLIX (Factor IX Fc fusion protein) for the treatment of severe Hemophilia A and B in multiple countries. In addition, in her role as SVP and Global Head of Safety and Benefit-Risk Management at Biogen for several years, she built a world-class organization accountable for patient safety and epidemiology in the pre and post-approval pipeline and

addressed complex issues in safety and benefit-risk management. While in that role she led the development of the risk management plan for TYSABRI® (natalizumab) and presented on this topic at an FDA Advisory Committee, leading to the approval of TYSABRI for the treatment of multiple sclerosis. She has served as the industry representative to the FDA's Risk Communication Advisory Committee and is a member of PhRMA's Clinical and Preclinical Development Committee. She is a member of the Board of Managers at BioMotiv. She received an MD degree and did her residency in internal medicine at McGill University in Montreal, Canada, completed a fellowship in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital in Boston, and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry. Dr. Bozic is a frequent lecturer and speaker on benefit-risk and other drug development topics nationally and internationally.

Junzhi (John) Yao, Ph.D.

Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. After graduation, he joined the Department of Chemistry at Wuhan University in July 1994 as an Assistant Professor. From 1995 to 1997, Dr. Yao worked at Hong Kong University of Science and Technology as a Visiting Scholar. He obtained Postdoctoral Research training at the Department of Chemistry at Southern Methodist University in Dallas, USA from 1997 to 1999 and conducted postdoctoral research at the Department of Chemistry and Faculty of Pharmacy at the University of Manitoba, Canada from 1999 to 2001.

Dr. Yao joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke. His contract research experience includes a 3-year collaboration effort with Pfizer.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada. He has been the CEO of TC Scientific since 2009. Under his leadership, TC Scientific has become one of the top CRO's in Canada.

Hui Cai, Ph.D.

VP of Corporate Alliances and Head of Communications, WuXi AppTec

Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate Communications. Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.

James (Jianguo) Yang, Ph.D.

Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China (Abpro, a Biotech company based in Boston area, USA). Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in several global 500 pharmaceutical companies, including in Abbott Lab Pharma Division (current AbbVie), MedImmune /AstraZeneca, Genzyme / Sanofi. Dr. Yang has published numerous patents and scientific papers, and is an editor advisor and reviewer for Bioprocess International (Journal), and Executive Director, Sino-America Pharmaceutical Association-NE (2012-2014), and also reviewer for several scientific journals. As international recognized scientist in biopharma Industry, Dr. Yang is a frequently-invited speaker for international biotech/biopharma conferences. Dr. Yang got his Ph.D. in cell/molecular biology from Illinois Institute of Technology, USA.

Yongzhong Wang, Ph.D.

Dr. Yongzhong Wang is the President of Pharmaceuticals and Executive VP of Simcere Pharmaceutical Group. He manages API manufacturing, sales and international regulatory affairs of the group, as well as Simcere Europe. Prior to Simcere, Dr. Wang was the CEO of Chengdu Kanghong Biotechnology Co., Ltd, a leading biotech company in China. He was instrumental for the development and commercialization of Conbercept, a fusion protein approved in 2013 in China as the longest lasting wAMD drug in the world. As CEO, he led the company to achieve triple digit growth and transitioned the previously single product-centric company to a full-fledged biotech business covering integrated R&D of multiple products, commercial manufacturing & distribution, and international development. In 2016, he successfully led his team to open a FDA IND for Conbercept to bypass Phases 1&2 and directly enter Phase 3 in the US, a rarity for novel biologics originally developed outside the US.

Prior to Kanghong Biotech, Dr. Wang worked at Genzyme in Cambridge, MA, where he led critical projects for a number of innovative products including MACI, the first tissue engineering product approved by the FDA for adult cartilage repair. While at Genzyme, Dr. Wang had two US/PCT patents and supported international marketing. He earned his Ph.D at Tufts University and had 10 peer reviewed publications with totally over 3000 citations.

Lynn Yang, MBA

杨云霞(Lynn Yang)，红杉资本中国基金董事总经理，主要专注于医疗健康领域的投资。

2015年5月加入红杉之前，杨云霞女士就职于君联资本医疗健康投资团队，主导完成了医疗健康多个细分行业的项目投资。在此之前，杨女士曾经在美国强生，GE等大型跨国公司工作。

杨云霞女士拥有美国杜克大学(Duke University) MBA学位及华中科技大学同济医科院临床医学硕士学位.

Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capital healthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare.

Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Kenneth I Kaitin, PhD

Professor and Director
Tufts Center for the Study of Drug Development
Tufts University School of Medicine

Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin also holds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel. A former President of the Drug Information Association, Dr. Kaitin is currently editor-in-chief of Expert Review of Clinical Pharmacology and serves as an expert consultant to the U.S. Department of Defense on bioterror countermeasure initiatives. An internationally recognized expert in drug development science and policy, Dr. Kaitin writes and speaks regularly on factors that contribute to the slow pace and high cost of drug development and efforts to improve R&D efficiency, and he has provided public testimony before the

U.S. Congress on drug development and policy issues. Dr. Kaitin serves on several public, private, and not-for-profit boards of directors. He received a BS from Cornell University and PhD in pharmacology from the University of Rochester.



Weng Xinyu, Ph.D

Weng Xinyu, Ph.D, is First Secretary of the Embassy of the People's Republic of China to the United States of America. As the primary point of contact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.

Before being transferred to the Chinese Embassy in Washington DC, Dr. Weng served as a Division Director in the Department of International Cooperation, CFDA since May 2013. In this capacity, he was responsible for bilateral cooperation with foreign food and drug regulatory authorities, non-governmental organizations, as well as foreign food and drug manufacturers. Dr. Weng was essential in the negotiations of the Implementing Arrangement between CFDA and US FDA regarding the cooperative mechanism of regulatory staff in 2014.

Prior to that, he served as Division Director in the Department of Drug Safety and Supervision, State Food and Drug Administration (SFDA). In that capacity, he coordinated implementation of the 2010 Edition Chinese Good Manufacturing Practices (GMP) for pharmaceutical products, and was an active participant in the International Conference of Drug Regulatory Authorities (ICDRA) organized by the World Health Organization.

Dr. Weng joined State Drug Administration (SDA) in 1998, holding various positions including Deputy Division Director in the Department of Drug Registration, and the Department of Drug Safety and Supervision. He was involved in carrying out traditional medicine registration and Good Clinical Practices (GCP) inspection, and in drafting Good Agricultural Practices (GAP) for herbal medicines.
Dr. Weng got his Ph.D from Shenyang Pharmaceutical University. He completed his MBA degree at the Birmingham University of the United Kingdom.

CABA 2017 AWARDS

Excellence in Innovation Award

GORDON J. FREEMAN, PhD
Professor, Medicine, Harvard Medical School

SHUQI CHEN, PhD
Founder, Chairman & CEO of IQuum

Leadership in Community Service Award

WuXi AppTec

Special Recognition for Community Service Award

Zhigang Wang, PhD
Fred Gilman, JD
Zhendong Zhu, PhD
Chaoyang Dai, PhD
Zhiyong Yang, PhD
Philip Zhang, PhD
Herong Yang
Qinglin Che, PhD
Zhihong Chen, PhD
Susan Qu, PhD
Xiangyang Yu, PhD

Excellence in Leadership Award

Shiwen Lin, PhD
Eric Shi, PhD

Ten-Year Service Award

Kevin Fang, PhD
Shallwei Sun
Liping Zhou, PhD
Sue Ma, MD

Five-Year Service Award

Carrie Liu, PhD
Henry Gu, JD
Yikai Wang, PhD
Shengfang Jin, PhD
Yueming Wang, MBA

Rising Star Award

Yin Chen, PhD
Jianfeng Hang, PhD
Ellen Fan
Qingqing Cao, PhD
Jingzhong Zhang, PhD
Jeannie Li, PhD
Jo Lee

Emerging Leader Award

Bo Ying, PhD
Jian Shao, PhD
Wendy Yang, MBA
Lan Cao, PhD
Shujia Dai, PhD
Youxin Zhang, PhD

Pioneers Award

Jun Han, PhD
Yihan Wang, PhD
Shiwen Lin, PhD
Erxi Wu, PhD
Lixin Shen, PhD
Junjun Wu, PhD
Zhao-Kui Wan, PhD

Dedicated Community Service Award

Howard Li, PhD
Wei Zhang, PhD
Xue Shui
Xiaoyong Zhao, PhD
Chunxiao Yu, PhD
Li Xing, PhD

Dedicated Coordinator Award

Ruiyi Dong
Jianyu Shang

Special Recognition for Entrepreneurial Leadership Award

Shallwei Sun
Yongzhong Wang, PhD

2017-2018 CABA Leadership Team

President, 2017-2018 (Beginning on May 6, 2017)
Kevin Fang, Ph.D., Sr. Director Med. Chemistry, Sunovion

President-Elect, 2018-2019
Bo Ying, Ph.D., Director, Formulation, PNA Innovations Inc.

Vice Presidents
Jian Shao, MBA, CEO, Sword Therapeutics

Wendy Yang, MBA
Manager, R&D Operational Planning and Capacity Management, Sanofi US

General Manager of Public Relations
Qingqing Cao, Ph.D. Sr Program manager, Insulet Corporation, Billerica, MA

General Manager of Operations
Ellen Fan, MSc., Ph.D. Candidate, Senior Scientist, Smith & Nephew, Andover, MA

Director of Scientific Programs
Lan Cao, Ph.D. VP, CMC, Battersea Biotech

Director of Communication
Shujia Dai, Ph.D.
Principal Research Investigator, Sanofi US

Treasurer
Liping Zhou, Ph.D., Sr. Scientist, Ipsen

CABA Legal Counsel
Fred Gilman, J.D., Attorney, Lynch, DeSimone & Nylen, LLP

President, CABA-TX
Shautong (Xiaotong) Song, Ph.D. Founding CEO of Icell Kealex Therapeutics

Chairman of the Board
Philip Zhang, Ph. D., J. D. Past President (2012-2013), Co-Founder and Chairman, Milstein Zhang & Wu LLC, Newton, MA

Board of Directors

Zhihong Chen, Ph.D. Past President (2011-2012)
Chaoyang Dai, Ph.D. Past President (2010-2011), President, Boston Biosolutions
Jun Han, Ph.D. Former Chairman of the Board, Founding President, CEO, SOTA International LLC, Boston, MA
Shiwen Lin, Ph.D., Former Chairman of the Board, Director, Process & Analytical Technologies, Agenus, Inc. Lexington, MA
Susan Qu, Ph.D. MBA, Past president (2015-2016), External Manufacturing Integrated Risk Manager, Genzyme Corporation, a division of Sanofi, Framingham, MA
Lixin Shen, Ph.D. President and CEO, Wuxi Howfond Biopharma Co., Ltd., Jiangsu, China
Eric Shi, Ph.D. Past president (2016-2017), Investigator, GSK
Zhao-Kui (ZK) Wan, Ph.D. Past-President (2009-2010), Head of Chemistry and a member of leadership team at Johnson & Johnson's Asian Pacific Discovery Center in Shanghai, China
Yihan Wang, Ph.D. Former Chairman of the Board, President, Shenzhen TargetRx, Inc., Shenzhen, China
Erxi Wu, Ph.D. Director, Neuro-oncology Research Center, Baylor Scott & White Health; Associate Prof., Texas A&M University
Junjun Wu, Ph.D. Past President (2007-2009), CEO, WuXi AllNature Biotech LLC, Jiangsu, China
Xiang Yang Yu, Ph.D. Past president (2013-2014), Program Manager, Accellient Partners LLC, Waltham, MA
Zhiyong Yang, Ph.D. Past president (2014-2015), Senior Principal Scientist, Pfizer, Cambridge, MA

Executive Committee, 2017-2018

Qinglin Che, Ph.D.
Sr. Scientist, CMC, Tetraphase Pharmaceuticals
Zhendong Zhu, Ph.D.
Principal Investigator, Celgene
Yin Chen, Ph.D.
MBA, Director, BD, Accelagen
Henry Gu, J.D.
Assistant General Counsel, IP, ARIAD Pharmaceuticals
Jeff Hang, Ph.D.
Director of Quality Systems, Makromed Inc.
Jo Lee, M.Ec.
Founder, Somebusiness, Inc.
Howard Hao Li, Ph.D., MBA
Cambridge Site Head, Novartis Knowledge Center, Novartis
Jeannie Li, Ph.D.
Sr. Scientist, Pfizer Inc.
Carrie Liu, Ph.D.
Associate Director of Technical Operation, Analytical, Vertex Pharphceuticals
Xue Shui, M.Sc.
Sr. Research Associate, Onkaido Therapeutics
Yueming Wang, MBA
CEO, Zhongyuan Pharmaceutical Co. Ltd., Beijing
Li Xing, Ph.D.
Sr. Director, WuxiAppTec
Chunxiao Yu, Ph.D.
Postdoc Res. Fellow, Harvard Medical School
Jingzhong Zhang, Ph.D.
Sr. Scientist, Medica Corporation
Wei Zhang, Ph.D.
Staff Scientist, Siemens Healthcare Diagnostics
Youxin Zhang Ph.D.
Managing Consultant, Navigant Consulting
Xiaoyong Zhao, Ph.D.
Sr. Scientist, Momenta Pharmaceuticals
Ben Wei, Ph.D., MBA
Global Business Manager, PerkinElmer
Cindy Yang, Ph.D.
Associate Director, Contracts and Alliance Management, Biogen Inc.

CABA Advisors

Youssef Bennani, Ph.D. Site Head, Vertex Pharmaceuticals Inc.-Canada

Tim Clackson, Ph.D. President of Research and Development and Chief Scientific Officer, Ariad Pharmaceuticals Inc., Cambridge, MA

Yuan-Hua Ding, Ph.D. Senior Director & Head of External R&D Innovation - Asia, Pfizer

Pierre Dodion, M.D., MBA, Sr. VP, Corporate Development, Ariad Pharmaceuticals Inc., Cambridge, MA

Chen Li, Ph.D. Chief Executive Officer, Hua Medicine, Inc., Shanghai, China

Luke Li, Ph.D. Exec Director, Head of Global Biotherapeutic Technologies, Bio-Innovation, Pfizer

Shi Li, Ph.D. CEO, Zerun Biotechnology, Shanghai, CHINA

Yuanli Liu, Ph.D. Director of China Initiative, Sr. Lecturer on International Health, Dept. of Global Health and Population, Harvard School of Public Health

Dawei Ma, Ph.D. Professor, Shanghai Institute of Organic Chemistry, Shanghai, China

Tarek Mansour, Ph.D. EVP of Research & Development, Xenon Pharmaceuticals Inc., Vancouver, Canada

Tse Ping, Chairman, Sino Biopharmaceutical Ltd., Beijing, China

John Piwinski, Ph.D. Principal, JJPiwinski Pharma Consulting, LLC, New York, NY

Steve Projan, Ph.D. Sr. V.P. R&D, Innovative Medicines Head of Infectious Diseases & Vaccines, MedImmune, Gaithersburg, MD

Tomi Sawyer, Ph.D. Chief Scientific Officer and Senior Vice-President, Aileron Therapeutics, Cambridge, MA

Liming Shao, Ph.D. Professor, Fudan University, Shanghai, China

Suvit Thaisrivongs, Ph.D. Vice President, Pfizer, Inc., Cambridge. MA

Roger Tung, Ph.D. CEO and President, Concert Pharmaceuticals, Lexington, MA

Yibin Xiang, Ph.D. CSO, Sanhome Pharma

Sunny Xie, Ph.D. Professor, Northeastern University

Gangfeng Xu, Ph.D. Divisional Vice President, Corporate Licensing & Acquisitions at Abbott Laboratories

Steve Yang, Ph.D. Executive VP & COO, Wuxi Apptec

Howard Yuwen, Ph.D. Co-founder & VP Corporate Development & Regulatory Affairs, Genesun Pharmaceuticals

Zhaohui Sunny Zhou, Ph.D. Associate Professor, Department of Chemistry and Chemical Biology and Faculty Fellow, Barnett Institute of Chemical and BiologicalAnalysis, Northeastern University

CABA Thank the dedicated service from the retired EC members: *Zhigang Wang, Ph.D.* and *Sue Ma, M.D.*, and also the retired VP: *Zhendong Zhu, Ph.D.*.

Chinese-American BioMedical Association

美中生物医药协会

CABA Mission Statement

- To promote science, technology, and business collaboration in biotech/pharmaceutical industry ;
- To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;
- To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;
- To embrace advancement of science and commercialization of innovation that will benefit human health;
- To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: cabaconnect@gmail.com
P. O. Box 426157
Cambridge, MA 02142